YALÇIN, Ş. Et Al. 2018. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet , vol.392, no.10142 , 123-133.

YALÇIN, Ş., ÖZGÜROĞLU, M., shitara, K., bang, y. j., bartolomeo, m. d., mandala, m., ... ryu, m.(2018). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet , vol.392, no.10142, 123-133.

YALÇIN, ŞUAYİB Et Al. "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial," Lancet , vol.392, no.10142, 123-133, 2018

YALÇIN, ŞUAYİB Et Al. "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial." Lancet , vol.392, no.10142, pp.123-133, 2018

YALÇIN, Ş. Et Al. (2018) . "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial." Lancet , vol.392, no.10142, pp.123-133.

@article{article, author={ŞUAYİB YALÇIN Et Al. }, title={Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial}, journal={Lancet}, year=2018, pages={123-133} }